ArticleJournal of molecular modeling2025
Investigating the molecular mechanisms of phytochemicals targeting Ras-related C3 botulinum toxin substrate 1 (Rac1) to inhibit breast cancer metastasis via endoplasmic reticulum stress and Wnt-PCP signaling pathway.
Article in Journal of molecular modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextBreast cancer metastasis remains a significant challenge in oncology, necessitating novel therapeutic approaches. Rac1 is a small GTPase involved in Wnt-planar cell polarity (Wnt-PCP) signaling and modulation of endoplasmic reticulum (ER) stress, and it has emerged as a promising target for inhibiting cancer progression. This study investigates the potential of cinnamaldehyde, a bioactive compound derived from cinnamon bark, as a potential Rac1 inhibitor. Computational analyses reveal that cinnamaldehyde exhibits higher binding specificity and efficacy to Rac1 than a reference inhibitor. Molecular dynamics (MD) simulations, essential dynamics, and MM-PBSA further confirm its stable binding with minimal impact on Rac1's structural conformation, which supports its potential as a lead compound for breast cancer therapy.
methodsA molecular docking study was performed using InstaDock and AutoDock Tools to assess cinnamaldehyde's binding affinity for Rac1. Pharmacokinetic properties were evaluated through SwissADME, and the PASS online tool was used for activity prediction. Protein-ligand interaction analyses were conducted using Discovery Studio Visualizer. All-atom MD simulations were performed for 500 ns using the GROMACS 2022 package with the CHARMM36 force field to analyze the stability of the cinnamaldehyde-Rac1 complex. The binding free energy computations were performed using the MM-PBSA approach.
Indexed as
Identifiers
40884633What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.